ClinicalTrials.Veeva

Menu

Endothelial Changes in Pseudoexfoliation Syndrome (PEX)

A

Assiut University

Status

Unknown

Conditions

Endothelial Cell Loss, Corneal

Treatments

Diagnostic Test: Specular Microscopy

Study type

Observational

Funder types

Other

Identifiers

NCT05194891
Endothelial Changes in PEX

Details and patient eligibility

About

this study aimed to evaluate the corneal endothelial cell changes before and after phacoemulsification in pseudoexfoliative patients relative to healthy adults.

Full description

Pseudoexfoliation syndrome (PEX) is an age related microfibrillopathy disorder characterized by the deposition of greyish white flaky exfoliative material in ocular and extraocular tissue. It commonly affects patients over 50 years old ((commonly in late 60s and 70s) with prevalence range from 0.5% to > 30%, Although it occurs in virtually every area of the world, a considerable racial variation exists in its incidence. It is relatively rare among African Americans and Eskimos. Prevalence is high in the Sami people who are indigenous of northern Europe. There is also a high prevalence in Arabic populations. It is also well known that patients with PXF develop cataracts early in their lives. Phacoemulsification is a preferred type of cataract surgery owing to fewer complications than other types. However, it still has significant undesirable hazardous as Posterior capsular rupture, vitreous loss, Retinal detachment, Cystoid macular oedema and Posterior capsule opacification. Also, it can enhance loss of corneal endothelial cells, thickness and density that may result in corneal decompensation and subsequent corneal transplantation. In patients with PXF, small pupils and weak zonular support may enhance Phacoemulsification complications. Non-contact Specular microscope is a non-invasive method for morphological analysis of corneal density of endothelial cells, "size change" (Polymegathism), "hexagonal change" (pleomorphism). Therefore, this technology plays an important role in preoperative evaluation, surgical design and postoperative care.

Enrollment

100 estimated patients

Sex

All

Ages

50 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Patient age is above50 years.
  2. Patient with nuclear cataract grade II, III.
  3. Clear cornea with no evidence of endothelial disease.
  4. Endothelial cell density more than 1000\mm2.
  5. Normal anterior chamber depth and dilatable pupil.
  6. No active ocular disease or inflammation.
  7. Pseudoexfoliative patients.

Exclusion criteria

  1. History of previous trauma, intraocular surgery or ocular surface infection in recent two weeks.
  2. Presence of any corneal opacity, endothelial disease, scarring or dystrophies.
  3. Pseudoexfoliative glaucoma.
  4. Patients age below 50 years.
  5. Endothelial cell count less than 1000\mm2.

Trial contacts and locations

0

Loading...

Central trial contact

Hassan Shams Eldeen, Assis. Prof; Shymaa Ahmed, Doctor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems